Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 9/20 | 0.46 |
| ▸ | PDE2A | O00408 | 7/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL701610 | 1.00 | KIF11 (0.46) | KIF11PDE2AKDM1AAKR1C3AKR1C2 | |
| SCHEMBL21711983 | 1.00 | KIF11 (0.46) | KIF11PDE2AKDM1AAKR1C3AKR1C2 | |
| Hydrochloric Acid SCHEMBL28665216 | 0.98 | KIF11 (0.44) | KIF11PDE2AKDM1AAKR1C3AKR1C2 | |
| Hydrochloric Acid SCHEMBL14121846 | 0.98 | KIF11 (0.44) | KIF11PDE2AKDM1AAKR1C3AKR1C2 | |
| Hydrochloric Acid SCHEMBL14121536 | 0.98 | KIF11 (0.44) | KIF11PDE2AKDM1AAKR1C3AKR1C2 | |
| Hydrochloric Acid SCHEMBL28665215 | 0.98 | KIF11 (0.44) | KIF11PDE2AKDM1AAKR1C3AKR1C2 | |
| SCHEMBL16649741 | 0.85 | KIF11 (0.43) | KIF11PDE2AKDM1AAKR1C3AKR1C2 | |
| SCHEMBL296445 | 0.85 | PDE2A (0.43) | PDE2AAKR1C3AKR1C2 | |
| SCHEMBL5019023 | 0.85 | PDE2A (0.43) | PDE2AAKR1C3AKR1C2 | |
| SCHEMBL2399327 | 0.85 | PDE2A (0.43) | PDE2AAKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2681215-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2015-04-22 | — | — | EP | claimed |
| CN-103635472-B | Serine/threonine kinase inhibitor | 阵列生物制药公司 | 2018-01-12 | — | — | CN | disclosed |
| US-20090099195-A1 | Therapeutic Compounds 570 | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099195-A1 | Therapeutic Compounds 570 | OPRL1, OPRK1, OPRM1 | KIF11 1856/4885PDE2A 334/4885KDM1A 3188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.